Dr. Palmer joins BillionToOne from Biotech Start-Up Management, where he was an adviser, according to LinkedIn. He has also served as chief medical officer of Tempus Labs and vice president of medical affairs at Foundation Medicine and Genomic Health.
In his new role, Dr. Palmer will guide BillionToOne through its launch of Northstar Select and Northstar Response, according to a Jan. 23 news release from the company. The Northstar liquid biopsy assays are now available for patients with late stage solid tumors.
Northstar Select guides therapy selection using an 81-gene, sequencing-based panel. Meanwhile, Northstar Response is a methylation-based assay that uses a single blood sample to help clinicians determine whether a patient is responding to therapy, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.